See more : Havila Shipping ASA (HAVI.OL) Income Statement Analysis – Financial Results
Complete financial analysis of TAAT Global Alternatives Inc. (TOBAF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TAAT Global Alternatives Inc., a leading company in the Tobacco industry within the Consumer Defensive sector.
You may be interested
- Falcon Gold Corp. (FG.V) Income Statement Analysis – Financial Results
- Canon Inc. (CAJ) Income Statement Analysis – Financial Results
- RAMM Pharma Corp. (RAMMF) Income Statement Analysis – Financial Results
- EROAD Limited (ERD.NZ) Income Statement Analysis – Financial Results
- Wind Works Power Corp. (WWPW) Income Statement Analysis – Financial Results
TAAT Global Alternatives Inc. (TOBAF)
About TAAT Global Alternatives Inc.
TAAT Global Alternatives Inc., through its subsidiary, TAAT International LLC, manufactures and distributes hemp cigarettes under the Wild Hemp brand name in Canada and the United States. The company was formerly known as TAAT Lifestyle & Wellness Ltd. and changed its name to TAAT Global Alternatives Inc. in April 2021. TAAT Global Alternatives Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 94.62M | 42.54M | 2.56M | 171.19K | 0.00 | 0.00 | 889.77K | 149.45K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 92.11M | 38.79M | 1.66M | 100.94K | 18.92K | 15.20K | 1.05M | 204.45K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.51M | 3.74M | 905.36K | 70.25K | -18.92K | -15.20K | -163.00K | -55.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 2.65% | 8.80% | 35.36% | 41.04% | 0.00% | 0.00% | -18.32% | -36.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 45.17K | 238.27K | 505.96K | 183.43K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 4.36M | 23.86M | 24.56M | 8.08M | 963.00K | 977.11K | 1.34M | 1.50M | 1.26M | 3.20M | 2.70M | 946.74K | 81.45K | 171.63K | 128.64K | 74.52K | 0.00 | 0.00 |
| Selling & Marketing | 251.22K | 2.08M | 8.11M | 1.41M | 70.29K | 99.46K | 552.85K | -17.07K | 305.92K | 635.71K | 270.08K | 24.28K | 32.54K | 6.50K | 9.70K | 3.76K | 0.00 | 0.00 |
| SG&A | 9.10M | 25.94M | 32.67M | 9.50M | 1.03M | 1.08M | 1.90M | 1.50M | 1.57M | 3.84M | 2.97M | 971.02K | 113.99K | 178.12K | 138.33K | 78.27K | 82.38K | 3.99K |
| Other Expenses | 0.00 | 1.86M | 583.46K | 119.49K | -540.63K | 76.65K | 0.00 | 17.07K | 136.25K | 94.20K | 12.73M | 1.33M | 624.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.14M | 28.03M | 33.76M | 9.80M | 492.67K | 1.60M | 1.90M | 1.50M | 1.70M | 3.87M | 15.77M | 2.30M | 114.62K | 178.12K | 138.33K | 78.27K | 82.38K | 3.99K |
| Cost & Expenses | 101.25M | 66.83M | 35.42M | 9.90M | 492.67K | 1.60M | 2.96M | 1.70M | 1.70M | 3.87M | 15.77M | 2.30M | 114.62K | 178.12K | 138.33K | 78.27K | 82.38K | 3.99K |
| Interest Income | 9.46K | 226.47K | 671.00 | 23.68K | 705.00 | 1.09K | 1.21K | 5.26K | 0.00 | 0.00 | 0.00 | 0.00 | 8.97K | 7.75K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 742.74K | 226.47K | 145.70K | 23.68K | 12.72K | 10.61K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 303.00 | 800.00 | 423.00 | 203.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.55M | 1.56M | 583.46K | 119.49K | 18.92K | 15.20K | 7.22K | 94.93K | 11.95M | 8.88K | -35.61K | 0.00 | 9.27K | 8.55K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -7.77M | -22.85M | -32.63M | -11.14M | -1.01M | -1.57M | -1.84M | -1.46M | 10.24M | -3.61M | -15.73M | -2.30M | -105.32K | -170.38K | -138.33K | -78.27K | -82.38K | -3.99K |
| EBITDA Ratio | -8.21% | -53.07% | -1,260.20% | -5,613.74% | 0.00% | 0.00% | -206.72% | -3,536.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -6.63M | -24.14M | -32.85M | -9.73M | -454.22K | -1.60M | -2.06M | -1.54M | -1.70M | -3.75M | -15.70M | -2.30M | -114.92K | -178.92K | -138.33K | -78.27K | -82.38K | -3.99K |
| Operating Income Ratio | -7.01% | -56.74% | -1,282.99% | -5,683.54% | 0.00% | 0.00% | -231.46% | -1,028.43% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.36M | -3.56M | -6.25M | -1.73M | 536.15K | -35.20K | 77.62K | 3.83M | -11.95M | -405.07K | -156.96K | 101.01K | 8.97K | -348.21K | -423.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -11.00M | -24.63M | -33.36M | -11.29M | -468.95K | -1.60M | -1.98M | 2.29M | -13.65M | -4.02M | -15.81M | -2.20M | -105.95K | -527.13K | -138.76K | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -11.62% | -57.91% | -1,302.88% | -6,592.37% | 0.00% | 0.00% | -222.74% | 1,534.82% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 120.97K | 270.68K | 145.70K | -85.27K | 50.47K | 4.88M | -84.84K | -3.83M | 2.00 | 242.72K | 71.90K | 0.00 | 0.00 | -56.21K | 138.76K | 78.48K | 82.64K | 4.02K |
| Net Income | -11.12M | -24.90M | -33.51M | -11.20M | -519.41K | -6.48M | -1.98M | 2.29M | -13.65M | -4.02M | -15.81M | -2.20M | -105.95K | -470.92K | -138.76K | -78.48K | -82.64K | -4.02K |
| Net Income Ratio | -11.75% | -58.55% | -1,308.57% | -6,542.56% | 0.00% | 0.00% | -222.74% | 1,534.82% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.00 | -2.39 | -3.52 | -1.93 | -0.28 | -6.76 | -3.09 | 8.80 | -51.76 | -16.60 | -77.14 | -20.03 | -1.35 | -8.32 | -9.23 | -5.22 | -6.57 | -0.54 |
| EPS Diluted | -1.00 | -2.39 | -3.52 | -1.93 | -0.28 | -6.76 | -3.09 | 8.00 | -51.76 | -16.60 | -77.14 | -20.03 | -1.35 | -8.32 | -9.23 | -5.22 | -6.57 | -0.54 |
| Weighted Avg Shares Out | 11.09M | 10.44M | 9.51M | 5.80M | 1.88M | 959.31K | 640.47K | 263.72K | 263.72K | 242.25K | 204.93K | 110.03K | 78.44K | 56.63K | 15.04K | 15.03K | 12.58K | 7.50K |
| Weighted Avg Shares Out (Dil) | 11.09M | 10.44M | 9.51M | 5.80M | 1.88M | 959.31K | 640.47K | 286.73K | 263.72K | 242.25K | 204.93K | 110.03K | 78.44K | 56.63K | 15.04K | 15.03K | 12.58K | 7.50K |
TAAT® Global Alternatives Inc. Announces Share Consolidation
LAS VEGAS and VANCOUVER, British Columbia, Sept. 28, 2023 (GLOBE NEWSWIRE) -- TAAT® GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the “Company” or “TAAT®”) announces that, pursuant to directors' resolutions, the Company will be consolidating all of its...
TAAT® Provides Update on Planned Austria Launch and Nasdaq Capital Market Application, as Well as Corporate Update for First Half of Calendar 2023
LAS VEGAS and VANCOUVER, British Columbia, May 09, 2023 (GLOBE NEWSWIRE) -- TAAT® GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the “Company” or “TAAT®”) hereby provides an update with respect to its planned launch of TAAT® in Austria,...
TAAT® Global Alternatives Inc. Files Financial Statements for its Fiscal Q1 2023
LAS VEGAS and VANCOUVER, British Columbia, April 03, 2023 (GLOBE NEWSWIRE) -- TAAT® GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the “Company” or “TAAT®”) announces that the financial statements for its Fiscal Q1 2023 (three-month period ended January...
TAAT® Global Alternatives Inc. to File Fiscal Q1 2023 Financials on Monday, April 3, 2023 and Provides General Update
LAS VEGAS and VANCOUVER, British Columbia, March 31, 2023 (GLOBE NEWSWIRE) -- TAAT® GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the “Company” or “TAAT®”) is pleased to announce that its financial statements for its Fiscal Q1 2023 (three-month...
TAAT® Provides Overview of Fiscal 2022 Financial Results
LAS VEGAS and VANCOUVER, British Columbia, March 24, 2023 (GLOBE NEWSWIRE) -- TAAT® GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the “Company” or “TAAT®”) is pleased to provide a summarized update of its performance during the Company's fiscal...
TAAT® Subsidiary Beyond Alternatives Begins Producing Second Batch of Jayvees Edibles
After launching Jayvees in February 2023, the Company's subsidiary Beyond Alternatives sold out its entire first commercial batch of Jayvees edibles in a 14-day period After launching Jayvees in February 2023, the Company's subsidiary Beyond Alternatives sold out its entire...
TAAT Provides Update on Status of MCTO
LAS VEGAS and VANCOUVER, British Columbia, March 15, 2023 (GLOBE NEWSWIRE) -- TAAT® GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the “Company” or “TAAT®”) is providing this update on the status of a management cease trade order granted...
TAAT® to Acquire Break Free™ Smoking Cessation Mobile App
LAS VEGAS and VANCOUVER, British Columbia, March 03, 2023 (GLOBE NEWSWIRE) -- TAAT® GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the “Company” or “TAAT®”) is pleased to announce that it has entered into a definitive agreement dated December...
TAAT Granted MCTO for Filing Extension of 2022 Financial Statements
LAS VEGAS and VANCOUVER, British Columbia, March 01, 2023 (GLOBE NEWSWIRE) -- TAAT® GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the “Company” or “TAAT®”) announces today that as a result of delays to its audit, the Company's annual...
Beyond Alternatives Exhibiting at Total Product Expo 2023
Beyond Alternatives LLC will have a booth at the three-day TPE event next week from February 22 to February 24; Beyond Alternatives LLC will continue introducing its inaugural brand “Jayvees” to the market at the exclusively B2B event Beyond Alternatives...
Source: https://incomestatements.info
Category: Stock Reports